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Purpose: Growing evidence suggests that hypoadiponectinemia may play a sig-
nificant role in the development of metabolic syndrome (MetS). Therefore, the re-
lationships between serum adiponectin with MetS and components of MetS were 
investigated in non-diabetic samples of drawn from the Koreans general popula-
tion. Materials and Methods: We performed a cross-sectional study in samples 
of older Koreans (age > 40 years) including 2,471 men and 3,463 women. MetS 
was defined according to the Asian modified criteria of the National Cholesterol 
Education Program Adult Treatment Panel III report. Serum adiponectin concen-
trations were measured by radioimmunoassay. Results: The median adiponectin 
level in MetS was significantly lower than that in non-MetS subjects in men (6.00 
vs. 8.00 µg/mL, p < 0.001) and women (10.12 vs. 11.74 µg/mL, p < 0.001). Adi-
ponectin concentration was negatively correlated with waist circumference and 
levels of triglyceride, C-reactive protein (CRP), fasting glucose, and insulin, and 
positively correlated with high-density lipoprotein and age in both genders (p < 
0.001). In a multivariate regression model after adjustment for age, body mass in-
dex, smoking, CRP, and lipid profiles, the odds ratio of MetS comparing extreme 
quartiles of adiponectin distribution was 0.32 [95% confidence interval (CI), 0.20 
to 0.50] in men and 0.57 (95% CI, 0.43 to 0.76) in women. Conclusion: Adipo-
nectin levels are independently associated with the phenotype of MetS, as well as 
components of MetS in the non-diabetic Korean general population.
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INTRODUCTION
Metabolic syndrome (MetS) is characterized by interrelated risk factors [hyperten-
sion, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, and 
elevated fasting glucose) and insulin resistance that identify individuals at in-
creased risk for type 2 diabetes and progression of cardiovascular disease.1
Adiponectin is the most abundant serum adipokine that has been recognized as a Relationships of Serum Adiponectin with Metabolic Syndrome
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4) hypertension: systolic blood pressure ≥ 130 mmHg, dia-
stolic blood pressure ≥ 85 mmHg; and 5) high fasting glu-
cose: serum glucose concentration ≥ 110 mg/dL. To evalu-
ate the consistency of our findings, we also used the criteria 
of the International Diabetes Federation (IDF),8 central obe-
sity (waist circumference ≥ 90 cm in men or ≥ 80 cm in wom-
en, modified using WHO Asia Pacific guidelines) plus any 
two of the following four factors: 1) elevated triglyceride 
level: > 150 mg/dL (1.69 mmol/L); 2) reduced HDL choles-
terol: < 40 mg/dL (1.04 mmol/L) in males or < 50 mg/dL 
(1.29 mmol/L) in females; 3) elevated blood pressure: sys-
tolic blood pressure (BP) ≥ 130 or diastolic BP ≥ 85 mmHg; 
and 4) elevated fasting plasma glucose  ≥ 100 mg/dL. 
Laboratory measurements 
A venous blood sample was drawn from each subject after 
fasting for 12 hours or overnight. The samples were stored at 
- 80°C until assay. The samples for adiponectin concentration 
were analysed within one week after centrifugation. The se-
rum concentrations of adiponectin were measured by radio-
immunoassay (RIA)(LINCO Research, Inc., St. Louis, MO, 
USA). The intra-assay and interassay coefficients of varia-
tion for serum adiponectin assays ranged between 2.9% and 
6.6%. Fasting glucose and insulin were determined by a glu-
cose oxidase-based assay and double-antibody RIA, respec-
tively. Serum total cholesterol and triglyceride concentrations 
were determined by enzymatic methods. HDL-cholesterol 
was measured enzymatically after heparin and calcium pre-
cipitation. Insulin resistance was calculated using the homeo-
stasis assessment (HOMA-IR) model using the following 
formula: fasting insulin (µIU/mL) x fasting plasma glucose 
(mmol/L)/22.5.  
Statistical analysis
Continuous variables are presented as means and standard 
deviations for clinical characteristics or medians and inter-
quartile ranges for adiponectin levels. These were compared 
using the unpaired t-test or the Mann-Whitney U-test. The 
distribution of adiponectin concentrations was markedly 
skewed and log-transformed in analyses where normality 
was required. Pearson’s correlation coefficients were used 
to establish the relationships between adiponectin concen-
trations (log-transformed) and clinical or laboratory param-
eters of MetS. 
Multivariate stepwise logistic regression analysis was used 
to assess the independent association for the presence or ab-
sence of MetS as the dichotomous dependant variable in 
key regulator of insulin sensitivity, tissue inflammation, en-
dothelial function, and lipid metabolism.1-3 Moreover, a 
growing body of evidence suggests that hypoadiponec-
tinemia may play a significant role in the development of 
MetS.4,5 However, little is known about the significance of 
circulating adiponectin as a surrogate marker for MetS itself 
and components of MetS in a non-diabetic general popula-
tion. Therefore, we sought to address this question and to 
identify potential relationships between circulating adiponec-
tin concentration and MetS as well as components of MetS.
MATERIALS AND METHODS
Study subjects 
The study subjects were selected from four rural areas as en-
rolled in the Korean Genomic Rural Cohort (KGRC), an on-
going epidemiologic study conducted on a representative 
sample of older (age > 40) Koreans. A total of 5,934 Korean 
non-diabetic adult subjects (2,471 men and 3,463 women) 
were enrolled in the KGRC between November 2005 and 
December 2006. None of the subjects had a self-reported 
medical history of cardiovascular disease, diabetes, or cancer, 
and all responded to a questionnaire on their medical-social 
history and life style characteristics. Subjects were excluded 
if they had been treated with any agents for hypertension (n = 
676), hyperlipidemia (n = 563), or obesity (n = 102). 
The study subjects are expected to be followed with bi-
annual health check-ups with a physical examination, sero-
logic tests, and genomic studies for ten years. All subjects 
provided informed consent, and the study protocol was ap-
proved by the Institutional Review Board of Wonju Chris-
tian Hospital. 
Definition of MetS
We used the definition for MetS suggested by the National 
Cholesterol Education Program Adult Treatment Panel III 
report (ATP III).6 However, the criterion for abdominal obesi-
ty was adopted from the World Health Organization (WHO) 
Asian Pacific Guideline.7 We defined MetS as the presence 
of at least three of the following abnormalities: 1) abdomi-
nal obesity: waist circumference ≥ 90 cm in men or ≥ 80 cm 
in women, modified using Asia Pacific WHO guidelines; 2) 
hypertriglyceridemia: a serum triglyceride concentration ≥ 
150 mg/dL (1.69 mmol/L); 3) low HDL cholesterolemia: a 
serum HDL cholesterol concentration < 40 mg/dL (1.04 
mmol/L) for men or < 50 mg/dL (1.29 mmol/L) in women, Sang-Baek Koh, et al.
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study cohort. The median adiponectin level in women 
(11.19 µg/mL) was significantly higher than in men (7.48 
µg/mL)(p < 0.001). The proportion of three or more char-
acteristics for MetS was 23.6% in men, compared with 
34.1% in women by ATP III. 
For every component of MetS examined, adiponectin 
levels were significantly lower in subjects who had compo-
nents of MetS than those who did not in both genders (p < 
0.001), with the exception of high blood pressure (p = 0.075 
in men and 0.720 in women)(Table 2). The median adipo-
nectin level in MetS was also significantly lower than that 
in non-MetS subjects for men (6.00 vs. 8.00 µg/mL, p < 
0.001) and women (10.12 vs. 11.74 µg/mL, p < 0.001). 
Table 3 shows interrelationships between serum adipo-
nectin levels and the total numbers of MetS components 
and HOMA-IR in both genders. A significantly linear de-
crease in adiponectin levels was observed according to total 
numbers of MetS components in both men and women. 
The median serum adiponectin levels in men with 0, 1, 2, 3, 
or ≥ 4 components of MetS were 8.90, 8.11, 7.31, 6.05, and 
quartiles of adiponectin values. Quartile cut-points were 5.18, 
7.48, and 10.74 µg/mL for men (n = 2,471) and 8.21, 11.19, 
and 14.62 µg/mL for women (n = 3,463). Results are ex-
pressed as odds ratios (ORs) together with 95% confidence 
intervals (CI). 
Age-adjusted ORs were first calculated (model 1), and 
the results were further adjusted for BMI as the continuous 
variable and smoking status as the dichotomous variable 
(model 2). Additional adjustments were carried out with 
CRP as the continuous variable (model 3) and cholesterol 
profile as the continuous variable (total cholesterol and 
HDL-cholesterol, model 4).
All analyses were performed using the SPSS statistical 
package for Windows (version 12.0, SPSS, Chicago, IL, 
USA), and p values < 0.05 were considered significant.
RESULTS
Table 1 shows the clinical and biochemical features of the 
Table 1. Baseline Characteristics of the Cohort Population
Men (n = 2,471) Women (n = 3,463) p value
Clinical characteristics
    Age (yrs) 56.6 ± 8.0 54.8 ± 8.3 < 0.001
    Current smoker, n (%) 929 (37.8) 131 (3.8) < 0.001
    BMI, kg/m
2 24.3 ± 4.3 24.4 ± 3.5    0.438
    Waist Circumference, cm 84.7 ± 8.0 81.0 ± 8.5 < 0.001
    Systolic BP, mmHg 130.3 ± 17.4 128.4 ± 17.7 < 0.001
    Diastolic BP, mmHg 83.4 ± 11.5   81.1 ± 11.4 < 0.001
Laboratory characteristics
    Total cholesterol, mg/dL 199.7 ± 37.6 205.5 ± 39.1 < 0.001
    Triglycerides, mg/dL   161.4 ± 108.8 141.0 ± 91.9 < 0.001
    HDL-cholesterol, mg/dL   46.2 ± 11.7   47.2 ± 11.0    0.001
    LDL-cholesterol, mg/dL 115.3 ± 32.6 122.7 ± 33.1 < 0.001
    Fasting glucose, mg/dL   96.5 ± 23.5   92.7 ± 18.5 < 0.001
    Fasting insulin, µIU/mL   7.75 ± 4.61   8.40 ± 4.95 < 0.001
    HOMA-IR* 1.54 (1.17 - 2.09) 1.59 (1.26 - 2.14)    0.162
    CRP, mg/L* 0.90 (0.47 - 1.95) 0.71 (0.38 - 1.51) < 0.001
    Adiponectin, µg/mL*   7.48 (5.18 - 10.74) 11.19 (8.21 - 14.62) < 0.001
No. of component for MetS, n (%)
    0   367 (14.9) 313 (9.0)
    1   825 (33.4)   860 (24.8)
    2   696 (28.2) 1,111 (32.1)
    3   422 (17.1)   793 (22.9)
    4 147 (5.9)   352 (10.2)
    5   14 (0.6)   34 (1.0)
Values are expressed as mean ± SD or number (%) if not stated otherwise.
BMI, body mass index; BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; HOMA-IR, homeostasis assess-
ment-insulin resistance; CRP, C-reactive protein; MetS, metabolic syndrome.
*Values are expressed as median (lower quartile-upper quartile), p value from Mann-Whitney U test.Relationships of Serum Adiponectin with Metabolic Syndrome
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= - 0.050), waist circumference (r = - 0.281), body mass index 
(BMI)(r = - 0.056), C-reactive protein (hsCRP)(r = - 0.053), 
fasting insulin (r = - 0.119), glucose (r = - 0.116), and HOMA-
IR (r = - 0.193), and positively correlated with HDL choles-
terol (r = 0.219) and age (r = 0.222). However, no significant 
relationship was found between systolic or diastolic blood 
pressure in men.
In women, adiponectin levels were negatively correlated 
with triglyceride levels (r = - 0.128), waist circumference (r 
= - 0.208), BMI (r = - 0.094), hsCRP (r = - 0.113), fasting in-
sulin (r = - 0.110), glucose (r = - 0.064), and HOMA-IR (r = 
5.74 µg/L, respectively (p trend < 0.001), while those in 
women were 12.82, 11.99, 11.38, 10.65, and 9.38 µg/L, re-
spectively (p trend < 0.001). Using the HOMA-IR, we also 
estimated the indices of insulin resistance among all sub-
jects. The serum adiponectin levels showed a significantly 
linear decrease with increasing quartiles of HOMA-IR in 
both men and women (p trend < 0.001). 
We estimated the correlation coefficients between serum 
adiponectin levels and various parameters of MetS. In men, 
adiponectin levels were negatively correlated with triglycer-
ide (r = - 0.153), low density lipoprotein (LDL) cholesterol (r 
Table 2. Median Serum Adiponectin Levels (Interquartile Ranges) among the Cohort According to the Pres-
ence or Absence of Each Component of the MetS Defined as ATP III
Men
n = 2,471 Present Absent p value
Obesity (n = 571) 6.14 (4.31 - 9.03) 7.86 (5.54 - 11.33) < 0.001
Hypertriglyceridemia (n = 1,036) 6.75 (4.74 - 9.75) 8.16 (5.66 - 11.59) < 0.001
Low HDL-cholesterol (n = 755) 6.63 (4.74 - 9.26) 7.89 (5.49 - 11.40) < 0.001
High blood pressure (n = 1,493)   7.30 (5.08 - 10.34) 7.80 (5.31 - 11.22) 0.075
Abnormal glucose (n = 249) 6.42 (4.52 - 9.80) 7.61 (5.29 - 10.95) < 0.001
≥ 3 characteristics (n = 456) 6.00 (4.32 - 8.53) 8.00 (5.62 - 11.33) < 0.001
Women
n = 3,463 Present Absent p value
Obesity (n = 1,221) 10.32 (7.66 - 13.50) 12.08 (8.97 - 15.64) < 0.001
Hypertriglyceridemia (n = 1,155) 10.21 (7.62 - 13.51) 11.72 (8.66 - 15.16) < 0.001
Low HDL- cholesterol (n = 2,184) 10.83 (7.95 - 14.08) 12.03 (8.97 - 15.35) < 0.001
High blood pressure (n = 1,729) 11.24 (8.19 - 14.70) 11.14 (8.28 - 15.54) 0.720
Abnormal glucose (n = 264) 10.18 (7.36 - 13.55) 11.28 (8.31 - 14.48) < 0.001
≥ 3 characteristics (n = 1,172) 10.12 (7.62 - 13.41) 11.74 (8.80 - 15.22) < 0.001
Values are expressed as median (lower quartile-upper quartile), p value from Mann-Whitney U-test.
ATP III, National Cholesterol Education Program Adult Treatment Panel III report; MetS, metabolic syndrome; HDL, high density lipo-
protein.
Table 3. Distribution of Serum Adiponectin Levels among the Cohort According to Presence of 0, 1, 2, 3, or ≥ 4 
Components of MetS and Quartile of HOMA-IR in Men (n = 2,471) and Women (n = 3,463) 
Adiponectin, µg/dL 
Men; n = 2,471
p trend
Adiponectin, µg/dL 
Women; n = 3,463
p trend
No. of MetS components < 0.001 < 0.001
    0   8.90 (6.24 - 12.74) 12.82 (9.58 - 16.70)
    1   8.11 (5.80 - 11.88) 11.99 (9.03 - 15.91)
    2   7.31 (5.06 - 10.05) 11.38 (8.29 - 14.36)
    3 6.05 (4.39 - 8.59) 10.65 (7.80 - 13.80)
    ≥ 4 5.74 (4.05 - 8.53)   9.38 (7.15- 12.33)
HOMA-IR < 0.001 < 0.001
    1st quartile (< 1.232)   8.70 (6.03 - 12.38) 12.14 (8.91 - 15.50)
    2nd quartile (1.232 - 1.573)   7.60 (5.27 - 10.16) 11.59 (8.79 - 15.32)
    3rd quartile (1.573 - 2.119)   7.13 (5.16 - 10.27) 11.20 (8.59 - 14.62)
    4th quartile (≥ 2.119) 6.27 (4.35 - 9.31)   9.97 (7.32 - 13.32)
Values are expressed as median (lower quartile-upper quartile). 
HOMA-IR, homeostasis assessment-insulin resistance; MetS, metabolic syndrome; No., numberSang-Baek Koh, et al.
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0.67), 0.58 (95% CI 0.43-0.80), and 0.32 (95% CI 0.20-
0.50), respectively, by ATP III criteria, whereas 0.52 (95% CI 
0.40-0.67), 0.62 (95% CI 0.46-0.85), and 0.21 (95% CI 0.13-
0.34), respectively, by IDF criteria. In the case of women, full 
adjustment ORs for MetS were 1.02 (95% CI 0.77-1.36), 
0.72 (95% CI 0.54-0.94), and 0.57 (95% CI 0.43-0.76), re-
spectively, by ATP III criteria, whereas 0.99 (95% CI 0.77-
1.23), 0.70 (95% CI 0.54-0.90), and 0.42 (95% CI 0.32-
- 0.133), and positively correlated with HDL cholesterol (r = 
0.169), and age (r = 0.187). However, there was no signifi-
cant relationship between LDL cholesterol and systolic or 
diastolic blood pressure in women. 
Table 4 shows ORs of MetS as a dependant variable, de-
fined by the ATP III and IDF, across quartiles of adiponec-
tin. Full adjustment (age, BMI, smoking, CRP, and choles-
terol levels) ORs for MetS in men were 0.51 (95% CI 0.40-
Table 4. Odds Ratio for Metabolic Syndrome Defined by ATP III and IDF Criteria According to Adiponectin 
Adiponectin (µg/mL)
Model 1
OR (95% CI)
p value
Model 2
OR (95% CI)
p value
Model 3 
OR (95% CI)
p value
Model 4 
OR (95% CI)
p value
ATP III in men
    1st quartile (< 5.18) 1.0
reference 1.0
reference 1.0
reference 1.0
reference
    2nd quartile (5.18 - 7.48)
0.49 
(0.39 - 0.62)
< 0.001
0.51 
(0.40 - 0.65)
< 0.001
0.51
(0.40 - 0.65)
< 0.001
0.51 
(0.40 - 0.67)
< 0.001
    3rd quartile (7.48 - 10.74)
0.46 
(0.35 - 0.61)
< 0.001
0.47 
(0.35 - 0.62)
< 0.001
0.47 
(0.35 - 0.62)
< 0.001
0.58 
(0.43 - 0.80)
   0.001
    4th quartile (≥ 10.74)
0.23 
(0.15 - 0.34)
< 0.001
0.22 
(0.14 - 0.33)
< 0.001
0.21 
(0.14 - 0.32)
< 0.001
0.32 
(0.20 - 0.50)
< 0.001 
IDF in men
    1st quartile (< 5.18) 1.0
reference 1.0
reference 1.0
reference 1.0
reference
    2nd quartile (5.18 - 7.48)
0.47 
(0.37 - 0.60)
< 0.001
0.49 
(0.38 - 0.64)
< 0.001
0.50 
(0.38 - 0.65)
< 0.001
0.52 
(0.40 - 0.67)
< 0.001
    3rd quartile (7.48 - 10.74)
0.55 
(0.42 - 0.73)
< 0.001
0.56 
(0.42 - 0.77)
< 0.001
0.57 
(0.42 - 0.77)
< 0.001
0.62 
(0.46 - 0.85)
   0.003
    4th quartile (≥ 10.74)
0.18 
(0.11 - 0.29)
< 0.001
0.17 
(0.10 - 0.28)
< 0.001
0.17 
(0.10 - 0.28)
< 0.001
0.21 
(0.13 - 0.34)
< 0.001
ATP III in women
    1st quartile (< 8.21) 1.0
reference 1.0
reference 1.0
reference 1.0
reference
    2nd quartile (8.21 - 11.19)
0.98 
(0.76 - 1.25)
   0.853
1.09 
(0.85 - 1.41)
   0.504
1.09 
(0.85 - 1.41)
   0.846
1.02
(0.77 - 1.36)
   0.869
    3rd quartile (11.19 - 14.62)
0.59 
(0.46 - 0.75)
< 0.001
0.65 
(0.50 - 0.83)
   0.001
0.65 
(0.50 - 0.83)
   0.001
0.72 
(0.54 - 0.94)
   0.017
    4th quartile (≥ 14.62)
0.39 
(0.31 - 0.50)
< 0.001
0.45 
(0.35 - 0.58)
< 0.001
0.45 
(0.35 - 0.58)
< 0.001
0.57 
(0.43 - 0.76)
< 0.001
IDF in women
    1st quartile (< 8.21) 1.0
reference 1.0
reference 1.0
reference 1.0
reference
    2nd quartile (8.21 - 11.19)
0.92 
(0.72 - 1.12)
   0.507
1.01 
(0.78 - 1.32)
   0.910
1.02 
(0.78 - 1.32)
   0.901
0.99 
(0.77 - 1.23)
   0.972
    3rd quartile (11.19 - 14.62)
0.61 
(0.49 - 0.77)
< 0.001
0.67 
(0.52 - 0.86)
   0.001
0.67 
(0.52 - 0.86)
   0.002
0.70 
(0.54 - 0.90)
   0.006
    4th quartile (≥ 14.62)
0.34 
(0.27 - 0.43)
< 0.001
0.38 
(0.29 - 0.49)
< 0.001
0.38 
(0.29 - 0.49)
< 0.001
0.42 
(0.32 - 0.55)
< 0.001
Model 1: adjusted for age; Model 2: adjusted for age, BMI and smoke; Model 3: adjusted for age, BMI, smoke and CRP; Model 4: adjusted for age, BMI, 
smoke, CRP, total cholesterol and HDL-cholesterol.
ATP III, National Cholesterol Education Program Adult Treatment Panel III report; IDF, International Diabetes Federation; OR, odds ratio; CI, confidence 
intervals.Relationships of Serum Adiponectin with Metabolic Syndrome
Yonsei Med J   http://www.eymj.org   Volume 52   Number 2   March 2011 239
hypertension have produced conflicting results in clinical 
settings.12,17-20 Adamczak, et al.17 reported that adiponectin 
levels are reduced in those with hypertension compared to 
BMI matched normotensive controls. In contrast, however, 
some studies found that adiponectin levels per se are not as-
sociated with systolic and diastolic blood pressure,12,20 and 
that higher adiponectin concentrations are also found in hy-
pertensive patients.19 Epidemiologic data suggest that five 
components responsible for MetS are clustered in various 
age and ethnic groups.12,21-23 Our present cohort showed a 
clustering of waist circumference, HDL-cholesterol, tri-
glyceride, and adiponectin levels and insulin resistance. 
However, blood pressure levels clustered into a separate fac-
tor of MetS, consistent with the results of the epidemiologic 
studies of Meigs, et al.23 and Mohan, et al.12 Thus, the rela-
tionship between adiponectin and blood pressure warrants 
further study with samples drawn from other populations. 
Another significant finding of the present study is that 
mean adiponectin levels were found to decrease significant-
ly with increasing numbers of MetS components in both 
men and women (p < 0.0001). In the WOSCOPS study, 
risk increased as the number of metabolic abnormalities 
rose up to 3.7-fold for risk of coronary heart disease (CHD) 
risk and 24-fold for diabetes in men with four or more 
baseline abnormalities.24 In the NHANES II survey, when 
those with no MetS risk factors were used as a reference 
group, the hazard ratios for CHD mortality were 2.10 (95% 
CI, 1.05 to 4.19) for those with one to two MetS risk factors 
and 3.51 (95% CI, 1.81 to 6.81) for those with MetS.25 The 
results of those large cohort studies indicate that the hazard 
ratios of coronary artery disease, diabetes and CHD mortal-
ity increase as the number of MetS components increase. 
Therefore, adiponectin might be a valid surrogate marker to 
expand traditional risk-factor-based treatment strategy. 
Recent studies have shown that adiponectin levels have an 
inverse association with new onset type 2 diabetes in popula-
tion-based studies. Adiponectin concentrations in the top ter-
tile had a 60% lower risk of incident type 2 in caucacian.26 In 
addition, the link between adiponectin levels and new onset 
diabetes was stronger in obese men and women.27 
While there are strong associations with low adiponectin 
levels and elevated risk of diabetes, controversies exist on 
the associations between adiponectin levels and vascular 
events. The initial data that higher adiponectin predisposes 
individuals to lower vascular risk has now been challenged.28 
High adiponectin levels have been linked to high rates of 
all-cause and cardiovascular mortality in prospective stud-
0.55), respectively, by IDF criteria.
c a DISCUSSION
We performed a large-scale cross-sectional study in an 
Asian non-diabetic sample to determine the relationships 
between serum adiponectin levels and MetS as well as its 
components. Our results clearly showed that serum adipo-
nectin is strongly associated with the MetS phenotype, and 
correlated with MetS components. Furthermore, serum adi-
ponectin is an independent protective adipokine for MetS 
in men and women under both ATP III and IDF criteria.
The adipocytes are active endocrine secretory cells that re-
lease adipokines including tumor necrosis factor (TNF)-α, 
interleukins (IL), leptin, visfatin, and adiponectin.9 Adipo-
nectin is the most abundant adipokine secreted by adipose 
cells that may regulator of insulin sensitivity. Adiponectin 
itself is also regulated by metabolic stress as well as a num-
ber of hormones, such as catecholamines, glucocorticoids, 
IL-6, TNF-α, growth hormone, thiazolidinediones and an-
drogens.10 Therefore, adiponectin is closely related obesity 
with metabolic derangement including insulin resistance.
In the present study, data were analyzed according to 
gender because mean serum adiponectin levels in men 
were typically lower than those in women (8.41 vs. 11.88 
µg/mL, p < 0.001), despite higher prevalence of MetS in 
women. Such gender differences in adiponectin levels have 
been previously reported.11-13 Androgen levels may play a 
role in gender differences, because androgens appear to 
have an inhibitory effect on adiponectin.14 Thus, it has been 
suggested that one cause of higher incidence of atheroscle-
rotic disease in men is decreased adiponectin concentration, 
since adiponectin is an anti-atherogenic protein. 
In the present study, circulating adiponectin levels were 
found to be associated significantly with the individual com-
ponents of MetS, CRP, and HOMA-IR. These results support 
the insulin-sensitizing, anti-inflammatory, and anti-dyslipid-
emic activities for adiponectin, consistent with reports from 
other investigators.11-13,15  On the other hand, systolic and di-
astolic blood pressures were clearly not associated with se-
rum adiponectin levels. In recent animal studies, adiponec-
tin-KO mice on a high salt diet developed hypertension, 
which was ameliorated by adiponectin replenishment. These 
results suggest that hypoadiponectinemia contributes to the 
development of obesity-related hypertension.16 However, 
studies of the relationship between adiponectin levels and Sang-Baek Koh, et al.
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tion, insulin sensitivity and plasma lipoproteins: evidence for inde-
pendent roles of age and sex. Diabetologia 2003;46:459-69.
16. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, et 
al. Adiponectin replenishment ameliorates obesity-related hyper-
tension. Hypertension 2006;47:1108-16.
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zawa Y. Decreased plasma adiponectin concentration in patients 
with essential hypertension. Am J Hypertens 2003;16:72-5.
18. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, 
Moniwa N, et al. Blockade of the renin-angiotensin system in-
creases adiponectin concentrations in patients with essential hy-
pertension. Hypertension 2003;42:76-81.
19. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlon-
go S, et al. Adiponectin in essential hypertension. J Nephrol 
2002;15:507-11.
20. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao 
CL, et al. Plasma adiponectin levels in overweight and obese 
Asians. Obes Res 2002;10:1104-10.
21. Aizawa Y, Kamimura N, Watanabe H, Aizawa Y, Makiyama Y, 
Usuda Y, et al. Cardiovascular risk factors are really linked in the 
metabolic syndrome: this phenomenon suggests clustering rather 
than coincidence. Int J Cardiol 2006;109:213-8.
22. Edwards KL, Burchfiel CM, Sharp DS, Curb JD, Rodriguez BL, 
Fujimoto WY, et al. Factors of the insulin resistance syndrome in 
nondiabetic and diabetic elderly Japanese-American men. Am J 
Epidemiol 1998;147:441-7.
23. Meigs JB, D’Agostino RB Sr, Wilson PW, Cupples LA, Nathan 
DM, Singer DE. Risk variable clustering in the insulin resistance 
syndrome. The Framingham Offspring Study. Diabetes 1997;46: 
1594-600.
24. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner 
ies.29,30 The roles of adiponectin in vascular outcome are 
currently not clear and further studies are needed. 
Therefore, the present cohort study (KGRC cohort), which 
was based on 10,000 rural Korean individuals, could define 
prognostic or additional values for adiponectin to predict a 
hard endpoint for cardiovascular disease in the future. 
Several limitations of the present study must be consid-
ered. First, this study was cross-sectional in design and was 
not intended to assess a cause-and-effect relationship be-
tween serum adiponectin and MetS or its components. How-
ever, the strength of our results was the fact that this study 
was based on a large population from representative rural 
regions of Korea. Second, the study included only one bio-
logically homogeneous east Asian sample. Nevertheless, 
we believe that these data are likely to be applied to other 
east Asian populations, because studies with other ethnic 
groups have linked circulating adiponectin to MetS in clini-
cal settings.12,31 
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